Botulinum toxin A, brain and pain

Progress in Neurobiology

Volumn 119-120, Issue , 2014, Pages 39-59

  Matak, Ivica ^a   Lacković, Zdravko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Axonal transport; Botulinum toxin type A; Pain; Sensory nervous system; Synaptosomal associated protein of 25kDa

Indexed keywords

BOTULINUM TOXIN A; OPIATE RECEPTOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; ANALGESIC AGENT;

ACETYLCHOLINE RELEASE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; BOTULISM; CELL TYPE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; EX VIVO STUDY; GABAERGIC TRANSMISSION; HUMAN; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERNALIZATION; MOTONEURON; NERVE CELL EXCITABILITY; NERVE ENDING; NERVE FIBER TRANSPORT; NONHUMAN; PHARMACODYNAMICS; POLYNEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SENSORY GANGLION; SENSORY NERVE CELL; ANIMAL; BRAIN; DRUG EFFECTS; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYNAPSE;

ANALGESICS; ANIMALS; AXONAL TRANSPORT; BOTULINUM TOXINS, TYPE A; BRAIN; HUMANS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNAPSES;

EID: 84905374107     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2014.06.001     Document Type: Review

References (244)

1. Akaike N., Shin M.C., Wakita M., Torii Y., Harakawa T., Ginnaga A., Kato K., Kaji R., Kozaki S. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J. Physiol. 2013, 591:1031-1043.
2. Alexiades-Armenakas M. Retrograde transport and transcytosis of botulinum toxin serotypes to the brain: analysis of potential neurotoxicity. J. Drugs Dermatol. 2008, 7:1006-1007.
3. Al-Saleem F.H., Ancharski D.M., Joshi S.G., Elias M., Singh A., Nasser Z., Simpson L.L. Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route. Infect. Immun. 2012, 80:4133-4142.
4. Anderson S., Krug H., Dorman C., McGarraugh P., Frizelle S., Mahowald M. Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain. J. Pain Res. 2010, 3:161-168.
5. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 2008, 28:3689-3696.
6. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43(Suppl. 1):S9-S15. Review.
7. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26:785-793.
8. Aoki K.R., Francis J. Update on antinociceptive mechanism hypothesis of botulinum toxin A. J. Parkinsonism Relat. Disord. 2011, 17:S28-S33.
9. Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A.P., Davis J.B., Dasgupta P., Fowler C.J., Anand P. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J. Urol. 2005, 174:977-982.
10. Arnon S.M., Schechter R., Inglesby T.V., Henderson D.A., Bartlet D.J., Michael S., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Philip K., Russell F.K., Swerdlow D.L., Tonat K., Working Group on Civilian Biodefense Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
11. Arezzo J.C. Possible mechanisms for the effects of botulinum toxin on pain. Clin. J. Pain 2002, 18:S125-S132.
12. Argoff C.E. A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain 2002, 18:S177-S181.
13. Auguet M., Favre-Guilmard C., Chabrier P.E. Analgesic effects of botulinum toxin A in an inflammatory pain model in rats: comparison of Dysport and Botox; synergistic interaction with morphine. Abstract Toxins. Toxicon 2008, 51(Suppl. 9).
14. Bach-Rojecky L., Lacković Z. Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat. Med. J. 2005, 46:201-208.
15. Bach-Rojecky L., Relja M., Lacković Z. Botulinum toxin type A in experimental neuropathic pain. J. Neural Transm. 2005, 112:215-219.
16. Bach-Rojecky L., Relja M., Lacković Z. Botulinum toxin type A in rat model of muscle hyperalgesia. J. Parkinsonism Relat. Disord. 2005, 11:106.
17. Bach-Rojecky L., Dominis M., Lacković Z. Lack of anti-inflammatory effects of botulinum toxin A in experimental models of inflammation. Fundam. Clin. Pharmacol. 2008, 22:503-509.
18. Bach-Rojecky L., Lacković Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol. Biochem. Behav. 2009, 94:234-238.
19. Bach-Rojecky L., Šalković-Petrišić M., Lacković Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effects after unilateral injection. Eur. J. Pharmacol. 2010, 633:10-14.
20. Bandala C., Perez-Santos J.L., Lara-Padilla E., Delgado Lopez G., Anaya-Ruiz M. Effect of botulinum toxin a on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac. J. Cancer Prev. 2013, 14:891-894.
21. Barash J.R., Arnon S.S. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 2014, 209:183-191.
22. Barnes M. Botulinum toxin-mechanisms of action and clinical use in spasticity. J. Rehabil. Med. 2003, (Suppl. 41):56-59.
23. Bartels F., Bergel H., Bigalke H., Frevert J., Halpern J., Middlebrook J. Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin. J. Biol. Chem. 1994, 269:8122-8127.
24. Bigalke H., Rummel A. Medical aspects of toxin weapons. Toxicology 2005, 214:210-220.
25. Binz T., Blasi J., Yamasaki S., Baumeister A., Link E., Südhof T.C., Jahn R., Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol. Chem. 1994, 269:1617-1620.
26. 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J. Cell Biol. 1986, 103:521-534.
27. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., De Camilli P., Südhof T.C., Niemann H., Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365:160-163.
28. Borodic G.E., Caruso P., Acquadro M., Chick S. Parry-Romberg syndrome vasculopathy and its treatment with botulinum toxin. Ophthal. Plast. Reconstr. Surg. 2014, 30:e22-e25.
29. Bossowska A., Majewski M. Botulinum toxin type A-induced changes in the chemical coding of dorsal root ganglion neurons supplying the porcine urinary bladder. Pol. J. Vet. Sci. 2012, 15:345-353.
30. Brin M.F., Fahn S., Moskowitz C., Friedman A., Shale H.M., Greene P.E., Blitzer A., List T., Lange D., Lovelace R.E., McMahon D. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord. 1987, 2:237-254.
31. Brodsky M.A., Swope D.M., Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet. Mov. (N. Y.) 2012, 2. tre-02-85-417-1.
32. Brook I. Infant botulism. J. Perinatol. 2007, 27:175-180.
33. Burstein R., Dodick D., Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon 2009, 54:624-627.
34. Caleo M., Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon 2009, 54:593-599.
35. Carli L., Montecucco C., Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009, 40:374-380.
36. Chapman M. The Global Botox Market Forecast to Reach $2.9 Billion by 2018 2012, Companies and Markets, (accessed September 2013). http://www.companiesandmarkets.com/News/Healthcare-and-Medical/The-global-botox-market-forecast-to-reach-2-9-billion-by-2018/NI2991.
37. Chen F., Kuziemko G.M., Stevens R.C. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect. Immun. 1998, 66:2420-2425.
38. Chen W.T., Yuan R.Y., Chiang S.C., Sheu J.J., Yu J.M., Tseng I.J., Yang S.K., Chang H.H., Hu C.J. OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin. J. Pain 2013, 29:305-310.
39. Cheng J., Liu W., Duffney L.J., Yan Z. SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors. J. Physiol. 2013, 591:3935-3947.
40. Chertow D.S., Tan E.T., Maslanka S.E., Schulte J., Bresnitz E.A., Weisman R.S., Bernstein J., Marcus S.M., Kumar S., Malecki J., Sobel J., Braden C.R. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006, 296:2476-2479.
41. Cheshire W.P., Abashian S.W., Mann J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994, 59:65-69.
42. Chou C.L., Lee S.H., Lu S.Y., Tsai K.L., Ho C.Y., Lai H.C. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J. Chin. Med. Assoc. 2010, 73:573-580.
43. Chuang Y., Yoshimura N., Huang C., Po H., Chancellor M.B. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 2004, 172:1529-1532.
44. Chuang Y.C., Yoshimura N., Huang C.C., Wu M., Chiang P.H., Chancellor M.B. Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J. Urol. 2008, 180:742-748.
45. Chuang Y.C., Yoshimura N., Huang C.C., Wu M., Chiang P.H., Chancellor M.B. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur. Urol. 2009, 56:159-166.
46. Climent J.M., Mondéjar-Gómez F., Rodríguez-Ruiz C., Díaz-Llopis I., Gómez-Gallego D., Martín-Medina P. Treatment of Morton neuroma with botulinum toxin A: a pilot study. Clin. Drug Investig. 2013, 33:497-503.
47. Coffield J.A., Yan X. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J. Pharmacol. Exp. Ther. 2009, 330:352-358.
48. Cohen L.G., Hallett M., Geller B.D., Hochberg F. Treatment of focal dystonias of the hand with botulinum toxin injections. J. Neurol. Neurosurg. Psychiatry 1989, 52:355-363.
49. Colasante C., Rossetto O., Morbiato L., Pirazzini M., Molgó J., Montecucco C. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol. Neurobiol. 2013, 48:120-127.
50. Crowner B.E., Brunstrom J.E., Racette B.A. Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin. Neuropharmacol. 2007, 30:310-313.
51. Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-133.
52. Da Silva L.F., Desantana J.M., Sluka K.A. Activation of NMDA receptors in the brainstem, rostral ventromedial medulla, and nucleus reticularis gigantocellularis mediates mechanical hyperalgesia produced by repeated intramuscular injections of acidic saline in rats. J. Pain 2010, 11:378-387.
53. Dodick D.W., Turkel C.C., DeGryse R.E., Aurora S.K., Silberstein S.D., Lipton R.B., Diener H.C., Brin M.F., PREEMPT Chronic Migraine Study Group OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010, 50:921-936.
54. Dolly J.O., Wang J., Zurawski T.H., Meng J. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS J. 2011, 278:4454-4466.
55. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
56. Dover N., Barash J.R., Arnon S.S. Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. J. Clin. Microbiol. 2009, 47:2349-2350.
57. Dover N., Barash J.R., Hill K.K., Xie G., Arnon S.S. Molecular characterization of a novel botulinum neurotoxin type H gene. J. Infect. Dis. 2014, 209:192-202.
58. Dressler D. Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J. Neurol. 2013, 260:701-713.
59. Drinovac V., Bach-Rojecky L., Matak I., Lacković Z. Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology 2013, 70:331-337.
60. Drinovac V., Bach-Rojecky L., Lacković Z. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. J. Neural Transm. 2014, 121:665-669.
61. Duc C., Catsicas S. Ultrastructural localization of SNAP-25 within the rat spinal cord and peripheral nervous system. J. Comp. Neurol. 1995, 356:152-163.
62. Duchen L.W., Rogers M., Stolkin C., Tonge D.A. Proceedings: suppression of botulinum toxin-induced axonal sprouting in skeletal muscle by implantation of an extra nerve. J. Physiol. 1975, 248(Suppl.):1P-2P.
63. Durham P.L., Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35-42.
64. Erbguth F.J. From poison to remedy: the chequered history of botulinum toxin. J. Neural Transm. 2008, 115:559-565.
65. Fabregat G., Asensio-Samper J.M., Palmisani S., Villanueva-Pérez V.L., De Andrés J. Subcutaneous botulinum toxin for chronic post-thoracotomy pain. Pain Pract. 2013, 13:231-234.
66. Favre-Guilmard C., Auguet M., Chabrier P.E. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur. J. Pharmacol. 2009, 617:48-53.
67. FDA US FOOD AND Drug Information: FDA Gives Update on Botulinum Toxin Safety Warnings; Established Names of Drugs Changed 2009, August 3, (accessed September 2013). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm175013.htm.
68. FDA US FOOD and Drug Information: Information for Healthcare Professionals: OnabotulinumtoxinA (Marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (Marketed as Dysport) and RimabotulinumtoxinB (Marketed as Myobloc) 2013, (accessed September 2013). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm.
69. Ferrari E., Gu C., Niranjan D., Restani L., Rasetti-Escargueil C., Obara I., Geranton S.M., Arsenault J., Goetze T.A., Harper C.B., Nguyen T.H., Maywood E., O'Brien J., Schiavo G., Wheeler D.W., Meunier F.A., Hastings M., Edwardson J.M., Sesardic D., Caleo M., Hunt S.P., Davletov B. Synthetic self-assembling clostridial chimera for modulation of sensory functions. Bioconjug. Chem. 2013, 24:1750-1759.
70. Filipović B., Bach-Rojecky L., Lacković Z. Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat. Fundam. Clin. Pharmacol. 2010, 24:43-45.
71. Filipović B., Matak I., Bach-Rojecky L., Lacković Z. Central action of peripherally applied botulinum toxin type a on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS ONE 2012, 7:e29803.
72. Filipović B., Matak I., Lacković Z. Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region. J. Neural Transm. 2014, 121:555-563.
73. Fischer A., Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10447-10452.
74. Foran P., Lawrence G.W., Shone C.C., Foster K.A., Dolly J.O. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry 1996, 35:2630-2636.
75. Francisco G.E., Tan H., Green M. Do botulinum toxins have a role in the management of neuropathic pain?: a focused review. Am. J. Phys. Med. Rehabil. 2012, 91:899-909.
76. ®): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs 2012, 72:825-845.
77. Franz D.R., Peter B., Jahrling P.B., Friedlander A.M., McClain D.J., Hoover D.L., Bryne R., Julie A., Pavlin J.A., Christopher G.W., Eitzen E.M. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278:399-411.
78. Freund B., Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J. Pain 2003, 4:159-165.
79. Gady J., Ferneini E.M. Botulinum toxin A and headache treatment. Conn. Med. 2013, 77:165-166.
80. Galli T., Garcia E.P., Mundigl O., Chilcote T.J., De Camilli P. v- and t-SNAREs in neuronal exocytosis: a need for additional components to define sites of release. Neuropharmacology 1995, 34:1351-1360.
81. Garner C.G., Straube A., Witt T.N., Gasser T., Oertel W.H. Time course of distant effects of local injections of botulinum toxin. Mov. Disord. 1993, 8:33-37.
82. Gazerani P., Staahl C., Drewes A.M., Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006, 122:315-325.
83. Gazerani P., Pedersen N.S., Staahl C., Drewes A.M., Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141:60-69.
84. Gazerani P., Au S., Dong X., Kumar U., Arendt-Nielsen L., Cairns B.E. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain 2010, 151:606-616.
85. Geppetti P., Rossi E., Chiarugi A., Benemei S. Antidromic vasodilatation and the migraine mechanism. J. Headache Pain 2012, 13:103-111.
86. Gerachshenko T., Blackmer T., Yoon E.J., Bartleson C., Hamm H.E., Alford S. Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition. Nat. Neurosci. 2005, 8:597-605.
87. Gerona R.R., Larsen E.C., Kowalchyk J.A., Martin T.F. The C terminus of SNAP25 is essential for Ca(2+)-dependent binding of synaptotagmin to SNARE complexes. J. Biol. Chem. 2000, 275:6328-6336.
88. Gerwin R. Botulinum toxin treatment of myofascial pain: a critical review of the literature. Curr. Pain Headache Rep. 2012, 16:413-422.
89. Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J. Neurol. Sci. 1997, 152:132-135.
90. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 1982, 46:86-94.
91. Göbel H., Heinze A., Reichel G., Hefter H., Benecke R. Dysport Myofascial Pain Study Group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006, 125:82-88.
92. Goode G.B., Shearn D.L. Botulism. A case with associated sensory abnormalities. Arch. Neurol. 1982, 39:55.
93. Grosse G., Grosse J., Tapp R., Kuchinke J., Gorsleben M., Fetter I., Höhne-Zell B., Gratzl M., Bergmann M. SNAP-25 requirement for dendritic growth of hippocampal neurons. J. Neurosci. Res. 1999, 56:539-546.
94. Grumelli C., Corradini I., Matteoli M., Verderio C. Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations. Cell Calcium 2010, 47:419-424.
95. Gu S., Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr. Top. Microbiol. Immunol. 2013, 364:21-44.
96. 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn-Schmiedeberg's Arch. Pharmacol. 1974, 281:47-56.
97. Harper C.B., Martin S., Nguyen T.H., Daniels S.J., Lavidis N.A., Popoff M.R., Hadzic G., Mariana A., Chau N., McCluskey A., Robinson P.J., Meunier F.A. Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J. Biol. Chem. 2011, 286:35966-35976.
98. He Y., Elias C.L., Huang Y.C., Gao X., Leung Y.M., Kang Y., Xie H., Chaddock J.A., Tsushima R.G., Gaisano H.Y. Botulinum neurotoxin A and neurotoxin E cleavage products of synaptosome-associated protein of 25kD exhibit distinct actions on pancreatic islet beta-cell Kv2, 1 channel gating. Pancreas 2008, 36:10-17.
99. Hu Y., Guan X., Fan L., Li M., Liao Y., Nie Z., Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J. Headache Pain 2013, 14:72.
100. Huang P.P., Khan I., Suhail M.S., Malkmus S., Yaksh T.L. Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing. PLoS ONE 2011, 6:e19126.
101. Huang X., Wheeler M.B., Kang Y.H., Sheu L., Lukacs G.L., Trimble W.S., Gaisano H.Y. Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells. Mol. Endocrinol. 1998, 12:1060-1070.
102. Humm A.M., Pabst C., Lauterburg T., Burgunder J.M. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp. Neurol. 2000, 161:361-372.
103. Ishida H., Zhang X., Erickson K., Ray P. Botulinum toxin type A targets Rho B to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor treated PC12 cells. J. Pharmacol. Exp. Ther. 2004, 310:881-889.
104. Ishikawa H., Mitsui Y., Yoshitomi T., Mashimo K., Aoki S., Mukuno K., Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked responses of albino and pigmented iris sphincter and dilator muscles. Jpn. J. Ophthalmol. 2000, 44:106-109.
105. Jabbari B., Machado D. Treatment of refractory pain with botulinum toxins-an evidence-based review. Pain Med. 2011, 12:1594-1606.
106. Jackson J.L., Kuriyama A., Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 2012, 307:1736-1745.
107. Jacky B.P., Garay P.E., Dupuy J., Nelson J.B., Cai B., Molina Y., Wang J., Steward L.E., Broide R.S., Francis J., Aoki K.R., Stevens R.C., Fernández-Salas E. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog. 2013, 9:e1003369.
108. Jakubowski M., McAllister P.J., Bajwa Z.H., Ward T.N., Smith P., Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 2006, 125:286-295.
109. Ji J., Salapatek A.M., Lau H., Wang G., Gaisano H.Y., Diamant N.E. SNAP-25, a SNARE protein, inhibits two types of K channels in esophageal smooth muscle. Gastroenterology 2002, 122:994-1006.
110. Jin L., Kollewe K., Krampfl K., Dengler R., Mohammadi B. Treatment of phantom limb pain with botulinum toxin type A. Pain Med. 2009, 10:300-303.
111. Jung H.H., Lauterburg T., Burgunder J.M. Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin. Neuroscience 1997, 78:469-479.
112. Kalandakanond S., Coffield J.A. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J. Pharmacol. Exp. Ther. 2001, 296:980-986.
113. Kalb S.R., Santana W.I., Geren I.N., Garcia-Rodriguez C., Lou J., Smith T.J., Marks J.D., Smith L.A., Pirkle J.L., Barr J.R. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem. 2011, 12:58.
114. Kanno T., Nishizaki T. A(2a) adenosine receptor mediates PKA-dependent glutamate release from synaptic-like vesicles and Ca efflux from an IP(3)- and ryanodine-insensitive intracellular calcium store in astrocytes. Cell. Physiol. Biochem. 2012, 30:1398-1412.
115. Kapural L., Stillman M., Kapural M., McIntyre P., Guirgius M., Mekhail N. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract. 2007, 7:337-340.
116. Karsenty G., Rocha J., Chevalier S., Scarlata E., Andrieu C., Zouanat F.Z., Rocchi P., Giusiano S., Elzayat E.A., Corcos J. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate 2009, 69:1143-1150.
117. Keller J.E., Neale E.A., Oyler G., Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999, 456:137-142.
118. Keller J.E., Neale E.A. The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem. 2001, 276:13476-13482.
119. Kerner J. Das Fettgift oder die Fettsaure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Wursten giftig wirkenden Stoffes. Cotta, Stuttgart; Tübingen 1822.
120. Kitamura Y., Matsuka Y., Spigelman I., Ishihara Y., Yamamoto Y., Sonoyama W., Kamioka H., Yamashiro T., Kuboki T., Oguma K. Botulinum toxin type A (150kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 2009, 59:1422-1429.
121. Koltzenburg M., Wall P.D., McMahon S.B. Does the right side know what the left is doing?. Trends Neurosci. 1999, 22:122-127.
122. Krämer H.H., Angerer C., Erbguth F., Schmelz M., Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J. Neurol. 2003, 250:188-193.
123. Krug H.E., Frizelle S., McGarraugh P., Mahowald M.L. Pain behavior measures to quantitate joint pain and response to neurotoxin treatment in murine models of arthritis. Pain Med. 2009, 10:1218-1228.
124. Kumada A., Matsuka Y., Spigelman I., Maruhama K., Yamamoto Y., Neubert J.K., Nolan T.A., Watanabe K., Maekawa K., Kamioka H., Yamashiro T., Kuboki T., Oguma K. Intradermal injection of botulinum toxin type A alleviates infraorbital nerve constriction-induced thermal hyperalgesia in an operant assay. J. Oral Rehabil. 2012, 39:63-72.
125. Kuo H.C. Repeated onabotulinumtoxin-A injections provide better results than single injection in treatment of painful bladder syndrome. Pain Phys. 2013, 16:E15-E23.
126. Kuruoǧlu R., Cengiz B., Tokçaer A. Botulism with sensory symptoms diagnosed by neuromuscular transmission studies associated with edrophonium responsiveness. Electromyogr. Clin. Neurophysiol. 1996, 36:477-480.
127. Lacković Z., Bach-Rojecky L., Šalković-Petrišić M. Antinociceptive effect of botulinum toxin type A in experiemtal diabetic neuropathy. Neurology 2006, 66:A376.
128. Lacković Z., Rebić V., Riederer P.F. Single intracerebroventricular injection of botulinum toxin type A produces slow onset and long-term memory impairment in rats. J. Neural Transm. 2009, 116:1273-1280.
129. Láinez-Andrés J.M. Onabotulinumtoxin A in the treatment of chronic migraine. Rev. Neurol. 2012, 54(Suppl. 2):S39-S50.
130. Langevin P., Peloso P.M., Lowcock J., Nolan M., Weber J., Gross A., Roberts J., Goldsmith C.H., Graham N., Burnie S.J., Haines T. Botulinum toxin for subacute/chronic neck pain. Cochrane Database Syst. Rev. 2011, 7. CD008626. 10.1002/14651858.CD008626.pub2.
131. 2+-evoked exocytosis from permeabilised chromaffin cells. Toxicology 2002, 181-182:249-253.
132. Lawrence G.W., Ovsepian S.V., Wang J., Aoki K.R., Dolly J.O. Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem. J. 2012, 441:443-452.
133. Lawrence G.W., Ovsepian S.V., Wang J., Aoki K.R., Dolly J.O. Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25. Neuropharmacology 2013, 70:287-295.
134. Lee W.H., Shin T.J., Kim H.J., Lee J.K., Suh H.W., Lee S.C., Seo K. Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced antinociceptive responses in mice. Anesth. Analg. 2011, 112:228-233.
135. Lee K., Gu S., Jin L., Le T.T., Cheng L.W., Strotmeier J., Kruel A.M., Yao G., Perry K., Rummel A., Jin R. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 2013, 9:e1003690.
136. Lucioni A., Bales G.T., Lotan T.L., McGehee D.S., Cook S.P., Rapp D.E. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008, 101(3):366-370.
137. Luvisetto S., Marinelli S., Lucchetti F., Marchi F., Cobianchi S., Rossetto O., Montecucco C., Pavone F. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. 2006, 1082:124-131.
138. Luvisetto S., Marinelli S., Cobianchi S., Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007, 145:1-4.
139. Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580:2011-2014.
140. Maksymowych A.B., Reinhard M., Malizio C.J., Goodnough M.C., Johnson E.A., Simpson L.L. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 1999, 67:4708-4712.
141. Majlesi G. GaAs laser treatment of bilateral eyelid ptosis due to complication of botulinum toxin type A injection. Photomed. Laser Surg. 2008, 26:507-509.
142. Marchand-Pauvert V., Aymard C., Giboin L.S., Dominici F., Rossi A., Mazzocchio R. Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J. Physiol. 2013, 591:1017-1029.
143. Marinelli S., Luvisetto S., Cobianchi S., Makuch W., Obara I., Mezzaroma E., Caruso M., Straface E., Przewlocka B., Pavone F. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience 2010, 171:316-328.
144. Marinelli S., Vacca V., Ricordy R., Uggenti C., Tata A.M., Luvisetto S., Pavone F. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS ONE 2012, 7:e47977.
145. Marino M.J., Terashima T., Steinauer J.J., Eddinger K.A., Yaksh T.L., Xu Q. Botulinum toxin B in the sensory afferent: transmitter release, spinal activation and pain behavior. Pain 2014, 155:674-684.
146. Martínez-Castrillo J.C., Del Real M.A., Hernandez Gonzalez A., De Blas G., Alvarez-Cermeño J.C. Botulism with sensory symptoms: a second case. J. Neurol. Neurosurg. Psychiatry 1991, 54:844-845.
147. Matak I., Bach-Rojecky L., Filipović B., Lacković Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011, 186:201-207.
148. Matak I., Riederer P., Lacković Z. Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem. Int. 2012, 61:236-239.
149. Matak I., Stracenski I., Lacković Z. Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats. J. Neural Transm. 2013, 120:141-144.
150. Mathew N.T., Kailasam J., Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008, 48:194-200.
151. Mathew N.T. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache 2011, 51(Suppl. 2):84-92.
152. McMahon H.T., Foran P., Dolly J.O., Verhage M., Wiegant V.M., Nicholls D.G. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J. Biol. Chem. 1992, 267:21338-21343.
153. Megighian A., Scorzeto M., Zanini D., Pantano S., Rigoni M., Benna C., Rossetto O., Montecucco C., Zordan M. Arg206 of SNAP-25 is essential for neuroexocytosis at the Drosophila melanogaster neuromuscular junction. J. Cell. Sci. 2010, 123:3276-3283.
154. Meng J., Ovsepian S.V., Wang J., Pickering M., Saase A., Aoki K.R., Lawrence G.W. Activation of TRPV 1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci. 2009, 29:4981-4992.
155. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J. Neurol. 2004, 251(Suppl. 1):I1-I7.
156. Meunier F.A., Schiavo G., Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J. Physiol. (Paris) 2002, 96:105-113.
157. Meunier F.A., Lisk G., Sesardic D., Dolly J.O. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci. 2003, 22:454-466.
158. Mika J., Rojewska E., Makuch W., Korostynski M., Luvisetto S., Marinelli S., Pavone F., Przewlocka B. The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 2011, 175:358-366.
159. Morenilla-Palao C., Planells-Cases R., García-Sanz N., Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J. Biol. Chem. 2004, 279:25665-25672.
160. Moreno-López B., de la Cruz R.R., Pastor A.M., Delgado-García J.M. Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: alterations of the discharge pattern. Neuroscience 1997, 81:437-455.
161. Morihara T., Mizoguchi A., Takahashi M., Kozaki S., Tsujihara T., Kawano S., Shirasu M., Ohmukai T., Kitada M., Kimura K., Okajima S., Tamai K., Hirasawa Y., Ide C. Distribution of synaptosomal-associated protein 25 in nerve growth cones and reduction of neurite outgrowth by botulinum neurotoxin A without altering growth cone morphology in dorsal root ganglion neurons and PC-12 cells. Neuroscience 1999, 91:695-706.
162. Morris J.L., Jobling P., Gibbins I.L. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H2627-H2635.
163. Nakano H., Okabe T., Hashimoto H., Sakaguchi G. Incidence of Clostridium botulinum in honey of various origins. Jpn. J. Med. Sci. Biol. 1990, 43:183-195.
164. Nakov R., Habermann E., Hertting G., Wurster S., Allgaier C. Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release. Eur. J. Pharmacol. 1989, 164:45-53.
165. Naumann M., Dressler D., Hallett M., Jankovic J., Schiavo G., Segal K.R., Truong D. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon 2013, 67:141-152.
166. Palomar F.J., Mir P. Neurophysiological changes after intramuscular injection of botulinum toxin. Clin. Neurophysiol. 2012, 123:54-60.
167. Park H.J., Lee Y., Lee J., Park C., Moon D.E. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth. 2006, 53:470-477.
168. Pastor A.M., Moreno-López B., De La Cruz R.R., Delgado-García J.M. Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: ultrastructural and synaptic alterations. Neuroscience 1997, 81:457-478.
169. Pavone F., Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins (Basel) 2010, 2:2890-2913.
170. Pellizzari R., Rossetto O., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1999, 354:259-268.
171. Popoff M.R., Bouvet P. Genetic characteristics of toxigenic Clostridia and toxin gene evolution. Toxicon 2013, 75:63-89.
172. Pozzi D., Condliffe S., Bozzi Y., Chikhladze M., Grumelli C., Proux-Gillardeaux V., Takahashi M., Franceschetti S., Verderio C., Matteoli M. Activity-dependent phosphorylation of Ser187 is required for SNAP-25-negative modulation of neuronal voltage-gated calcium channels. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:323-328.
173. Proietti S., Nardicchi V., Porena M., Giannantoni A. Attivita della tossina botulinica A in linee cellulari di cancro prostatico. Urologia 2012, 79:135-141.
174. Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem. Pharmacol. 2000, 59:1403-1406.
175. Ranoux D., Attal N., Morain F., Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 2008, 64:274-283.
176. Rapp D.E., Turk K.W., Bales G.T., Cook S.P. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J. Urol. 2006, 175:1138-1142.
177. Ravichandran E., Gong Y., Al Saleem F.H., Ancharski D.M., Joshi S.G., Simpson L.L. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J. Pharmacol. Exp. Ther. 2006, 318:1343-1351.
178. Ray P., Berman J.D., Middleton W., Brendle J. Botulinum toxin inhibits arachidonic acid release associated with acetylcholine release from PC12 cells. J. Biol. Chem. 1993, 268:11057-11064.
179. Ray P., Ishida H., Millard C.B., Petrali J.P., Ray R. Phospholipaise A2 and arachidonic acid-mediated mechanism of neuroexocytosis: a possible target of botidinum neurotoxin A other then SNAP-25. J. Appl. Toxicol. Suppl. 1999, 1:S27-S28.
180. Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur. J. Neurol. 1997, 4:S71-S73.
181. Relja M., Klepac N. Different doses of botulinum toxin A and pain responsiveness in cervical dystonia. Neurology 2002, 58:A474.
182. Relja M., Telarović S. Botulinum toxin in tension-type headache. J. Neurol. 2004, 251(Suppl. 1):I12-I14.
183. Relja M., Miletić V. Botulinum toxin type-A in the treatment of painful diabetic neuropathy: a prospective study. Neurology 2006, 66:A70.
184. Restani L., Antonucci F., Gianfranceschi L., Rossi C., Rossetto O., Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J. Neurosci. 2011, 31:15650-15659.
185. Restani L., Novelli E., Bottari D., Leone P., Barone I., Galli-Resta L., Strettoi E., Caleo M. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic 2012, 13:1083-1089.
186. Restani L., Giribaldi F., Manich M., Bercsenyi K., Menendez G., Rossetto O., Caleo M., Schiavo G. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog. 2012, 8(12):e1003087.
187. Rodriguez R.L., Fernandez H.H. Sustained benefit of painful legs moving toes syndrome with botulinum toxin type A. J. Clin. Neurosci. 2013, 20:1031-1032.
188. Russell A., Kavia R., Dasgupta P., Sahai A. The use of botulinum toxin for the treatment of urologic pain. Curr. Opin. Urol. 2013, 23:570-578.
189. Santini M., Fabri S., Sagnelli P., Manfredi M., Francia A. Botulism: a case associated with pyramidal signs. Eur. J. Neurol. 1999, 6:91-93.
190. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
191. Schulte-Mattler W.J., Opatz O., Blersch W., May A., Bigalke H., Wohlfahrt K. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J. Neurol. Sci. 2007, 260:38-42.
192. Schulte-Mattler W.J., Krack P. BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004, 109:110-114.
193. Scott A.B., Rosenbaum A., Collins C.C. Pharmacologic weakening of extraocular muscles. Invest. Ophthalmol. 1973, 12:924-927.
194. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus 1980, 17:21-25.
195. Seth J., Khan M.S., Dasgupta P., Sahai A. Botulinum toxin-what urologic uses does the data support?. Curr. Urol. Rep. 2013, 14:227-234.
196. Shimizu T., Shibata M., Toriumi H., Iwashita T., Funakubo M., Sato H., Kuroi T., Ebine T., Koizumi K., Suzuki N. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol. Dis. 2012, 48:367-378.
197. Shin M.C., Yukihira T., Ito Y., Akaike N. Antinociceptive effects of A1 and A2 type botulinum toxins on carrageenan-induced hyperalgesia in rat. Toxicon 2013, 64:12-19.
198. Silberstein S., Mathew N., Saper J., Jenkins S., for the BOTOX® Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000, 40:445-450.
199. Silberstein S.D., Blumenfeld A.M., Cady R.K., Turner I.M., Lipton R.B., Diener H.C., Aurora S.K., Sirimanne M., DeGryse R.E., Turkel C.C., Dodick D.W. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J. Neurol. Sci. 2013, 331:48-56.
200. Simpson L. The life history of a botulinum toxin molecule. Toxicon 2013, 68:40-59.
201. Singh J.A., Fitzgerald P.M. Botulinum toxin for shoulder pain. Cochrane Database Syst. Rev. 2010, 9. CD008271. 10.1002/14651858.CD008271.pub2.
202. Sluka K.A., Kalra A., Moore S.A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001, 24:37-46.
203. Soares A., Andriolo R.B., Atallah A.N., da Silva E.M. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst. Rev. 2012, 4. CD007533. 10.1002/14651858.CD007533.pub2.
204. Sobel J. Botulism. Clin. Infect. Dis. 2005, 41:1167-1173.
205. Stell R., Thompson P.D., Marsden C.D. Botulinum toxin in spasmodic torticollis. J. Neurol. Neurosurg. Psychiatry 1988, 51:920-923.
206. Sugii S., Ohishi I., Sakaguchi G. Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes. Infect. Immun. 1977, 16:910-914.
207. Sudhof T.C. A molecular machine for neurotransmitter release; synaptotagmin and beyond. Nat. Med. 2013, 19:8-13.
208. Sycha T., Samal D., Chizh B., Lehr S., Gustorff B., Schnider P., Auff E. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth. Analg. 2006, 102:509-516.
209. 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 2003, 42:461-469.
210. Tarsy D., First E.R. Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov. Disord. 1999, 14:1043-1045.
211. Thenganatt M.A., Fahn S. Botulinum toxin for the treatment of movement disorders. Curr. Neurol. Neurosci. Rep. 2012, 12:399-409.
212. Thyssen A., Hirnet D., Wolburg H., Schmalzing G., Deitmer J.W., Lohr C. Ectopic vesicular neurotransmitter release along sensory axons mediates neurovascular coupling via glial calcium signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15258-15263.
213. Torii Y., Akaike N., Harakawa T., Kato K., Sugimoto N., Goto Y., Nakahira S., Kohda T., Kozaki S., Kaji R., Ginnaga A. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. J. Pharmacol. Sci. 2011, 117:275-285.
214. Truong D.D., Stenner A., Reichel G. Current clinical applications of botulinum toxin. Curr. Pharm. Des. 2009, 15:3671-3680.
215. Tsai Y.C., Maditz R., Kuo C.L., Fishman P.S., Shoemaker C.B., Oyler G.A., Weissman A.M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16554-16559.
216. Tsui J.K., Eisen A., Stoessl A.J., Calne S., Calne D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986, 2:245-247.
217. Tugnoli V., Capone J.G., Eleopra R., Quatrale R., Sensi M., Gastaldo E., Tola M.R., Geppetti P. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007, 130:76-83.
218. Tyler H.R. Botulinus toxin: effect on the central nervous system of man. Science 1963, 139:847-848.
219. Upile T., Elmiyeh B., Jerjes W., Prasad V., Kafas P., Abiola J., Youl B., Epstein R., Hopper C., Sudhoff H., Rubin J. Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. Head Face Med. 2009, 5:20.
220. Vacca V., Marinelli S., Eleuteri C., Luvisetto S., Pavone F. Botulinum neurotoxin A enhances the analgesic effects on inflammatory pain and antagonizes tolerance induced by morphine in mice. Brain Behav. Immun. 2012, 26:489-499.
221. Vacca V., Marinelli S., Luvisetto S., Pavone F. Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opioid receptor expression in neuropathic mice. Brain Behav. Immun. 2013, 32:40-50.
222. Verderio C., Grumelli C., Raiteri L., Coco S., Paluzzi S., Caccin P., Rossetto O., Bonanno G., Montecucco C., Matteoli M. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 2007, 8:142-153.
223. Verderio C., Pozzi D., Pravettoni E., Inverardi F., Schenk U., Coco S., Proux-Gillardeaux V., Galli T., Rossetto O., Frassoni C., Matteoli M. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 2004, 41:599-610.
224. Voller B., Sycha T., Gustorff B., Schmetterer L., Lehr S., Eichler H.G., Auff E., Schnider P. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003, 61:940-944.
225. Waseem Z., Boulias C., Gordon A., Ismail F., Sheean G., Furlan A.D. Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst. Rev. 2010, 1. CD008257. 10.1002/14651858.CD008257.pub2.
226. Welch M.J., Purkiss J.R., Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245-258.
227. Wenham T.N. Botulism: a rare complication of injecting drug use. Emerg. Med. J. 2008, 25:55-56.
228. Wheeler A.H., Goolkasian P., Gretz S.S. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23:1662-1666.
229. Wheeler A., Smith H.S. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013, 306:124-146.
230. WHO: World Health Organisation Botulism. Fact Sheet N° 270 2013, (updated August 2013). http://www.who.int/mediacentre/factsheets/fs270/en/.
231. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn-Schmiedeberg's Arch. Pharmacol. 1976, 292:161-165.
232. Wiegand H., Wellhöner H.H. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn-Schmiedeberg's Arch. Pharmacol. 1977, 298:235-238.
233. Winocour S., Murad M.H., Bidgoli-Moghaddam M., Jacobson S.R., Bite U., Saint-Cyr M., Tran N.V., Lemaine V. A systematic review of the use of Botulinum toxin type A with subpectoral breast implants. J. Plast. Reconstr. Aesthet. Surg. 2014, 67:34-41.
234. Wohlfarth K., Schubert M., Rothe B., Elek J., Dengler R. Remote F-wave changes after local botulinum toxin application. Clin. Neurophysiol. 2001, 112:636-640.
235. Wright M.C., Cho W.J., Son Y.J. Distinct patterns of motor nerve terminal sprouting induced by ciliary neurotrophic factor vs. botulinum toxin. J. Comp. Neurol. 2007, 504:1-16.
236. Wu H., Sultana R., Taylor K.B., Szabo A. A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection versus Lidocaine/Depomedrol injection on residual and phantom limb pain: initial report. Clin. J. Pain 2012, 28:108-112.
237. Xiao L., Cheng J., Dai J., Zhang D. Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats. Pain Med. 2011, 12:1385-1394.
238. Xiao L., Cheng J., Zhuang Y., Qu W., Muir J., Liang H., Zhang D. Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med. 2013, 14:276-286.
239. Yiangou Y., Anand U., Otto W.R., Sinisi M., Fox M., Birch R., Foster K.A., Mukerji G., Akbar A., Agarwal S.K., Anand P. Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. J. Pain Res. 2011, 4:347-355.
240. Yuan R.Y., Sheu J.J., Yu J.M., Chen W.T., Tseng I.J., Chang H.H., Hu C.J. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009, 72:1473-1478.
241. Zamponi G.W. Regulation of presynaptic calcium channels by synaptic proteins. J. Pharmacol. Sci. 2003, 92:79-83.
242. Zhang P., Ray R., Singh B.R., Ray P. Mastoparan-7 rescues botulinum toxin-A poisoned neurons in a mouse spinal cord cell culture model. Toxicon 2013, 76:37-43.
243. Zhang X., Verge V.M., Wiesenfeld-Hallin Z., Piehl F., Hökfelt T. Expression of neuropeptides and neuropeptide mRNAs in spinal cord after axotomy in the rat, with special reference to motoneurons and galanin. Exp. Brain Res. 1993, 93:450-461.
244. Zúñiga C., Díaz S., Piedimonte F., Micheli F. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq. Neuropsiquiatr. 2008, 66:500-503.